Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.
Biomarkers
Cancer-Associated Fibroblasts
/ drug effects
Cell Line, Tumor
Cell Movement
Cell Proliferation
Cell Survival
/ drug effects
Epithelial-Mesenchymal Transition
/ drug effects
Exosomes
/ metabolism
Humans
Interleukin-6
/ metabolism
Mitomycin
/ pharmacology
Paracrine Communication
/ drug effects
Prognosis
STAT3 Transcription Factor
/ metabolism
Signal Transduction
/ drug effects
Urinary Bladder Neoplasms
/ genetics
Bladder cancer
CAFs
EMT
IL-6
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
11 Feb 2019
11 Feb 2019
Historique:
received:
30
05
2018
accepted:
05
02
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
30
5
2019
Statut:
epublish
Résumé
Cancer-associated fibroblasts (CAFs), activated by tumour cells, are the predominant type of stromal cells in cancer tissue and play an important role in interacting with neoplastic cells to promote cancer progression. Epithelial-mesenchymal transition (EMT) is a key feature of metastatic cells. However, the mechanism by which CAFs induce EMT program in bladder cancer cells remains unclear. To investigate the role of CAFs in bladder cancer progression, healthy primary bladder fibroblasts (HFs) were induced into CAFs (iCAFs) by bladder cancer-derived exosomes. Effect of conditioned medium from iCAFs (CM Cancer exosome-treated HFs showed CAFs characteristics with high expression levels of αSMA and FAP. We showed that the CM We conclude that CAFs promote aggressive phenotypes of non-invasive bladder cancer cells through an EMT induced by the secretion of IL-6.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-associated fibroblasts (CAFs), activated by tumour cells, are the predominant type of stromal cells in cancer tissue and play an important role in interacting with neoplastic cells to promote cancer progression. Epithelial-mesenchymal transition (EMT) is a key feature of metastatic cells. However, the mechanism by which CAFs induce EMT program in bladder cancer cells remains unclear.
METHODS
METHODS
To investigate the role of CAFs in bladder cancer progression, healthy primary bladder fibroblasts (HFs) were induced into CAFs (iCAFs) by bladder cancer-derived exosomes. Effect of conditioned medium from iCAFs (CM
RESULTS
RESULTS
Cancer exosome-treated HFs showed CAFs characteristics with high expression levels of αSMA and FAP. We showed that the CM
CONCLUSIONS
CONCLUSIONS
We conclude that CAFs promote aggressive phenotypes of non-invasive bladder cancer cells through an EMT induced by the secretion of IL-6.
Identifiants
pubmed: 30744595
doi: 10.1186/s12885-019-5353-6
pii: 10.1186/s12885-019-5353-6
pmc: PMC6371428
doi:
Substances chimiques
Biomarkers
0
Interleukin-6
0
STAT3 Transcription Factor
0
Mitomycin
50SG953SK6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Références
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
World J Urol. 2018 Feb;36(2):157-170
pubmed: 29147759
Sci Rep. 2016 Jun 23;6:28587
pubmed: 27335258
Cancers (Basel). 2015 Oct 14;7(4):2054-62
pubmed: 26473929
Nat Rev Cancer. 2009 Apr;9(4):239-52
pubmed: 19279573
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Mol Cancer Res. 2018 Jul;16(7):1196-1204
pubmed: 29636362
Int J Biochem Cell Biol. 2012 Jun;44(6):847-50
pubmed: 22433990
Cancer. 2016 Mar 15;122(6):842-51
pubmed: 26773572
Front Oncol. 2014 Mar 27;4:62
pubmed: 24734219
PLoS One. 2017 Jul 21;12(7):e0181725
pubmed: 28732081
Int J Cancer. 2013 May 1;132(9):1977-85
pubmed: 23034889
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Exp Med. 2014 Jul 28;211(8):1503-23
pubmed: 25071162
Mol Cancer. 2008 Oct 21;7:78
pubmed: 18939995
Sci Rep. 2015 Jul 08;5:11924
pubmed: 26152796
Oncotarget. 2017 Jun 2;8(35):59500-59508
pubmed: 28938653
J Thorac Oncol. 2016 Sep;11(9):1482-92
pubmed: 27287412
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancer Lett. 2014 Feb 1;343(1):80-9
pubmed: 24145153
J Surg Oncol. 2011 May 1;103(6):468-74
pubmed: 21480238
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Nat Rev Cancer. 2006 May;6(5):392-401
pubmed: 16572188
Biomaterials. 2017 Nov;145:233-241
pubmed: 28888113
Cancer Res. 2010 Sep 1;70(17):6945-56
pubmed: 20699369
Tumour Biol. 2017 Apr;39(4):1010428317697552
pubmed: 28378639
World J Urol. 2016 May;34(5):709-16
pubmed: 26394624
Dev Dyn. 2010 Jan;239(1):34-44
pubmed: 19623618
Semin Cancer Biol. 2013 Dec;23(6 Pt B):522-32
pubmed: 24012661
Oncotarget. 2017 Mar 28;8(13):20741-20750
pubmed: 28186964
Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):296-306
pubmed: 27750041
Oncol Lett. 2017 Sep;14(3):2611-2620
pubmed: 28927027
Mol Cancer. 2010 Jan 08;9:3
pubmed: 20059769
J Urol. 2002 Mar;167(3):1475-81
pubmed: 11832773
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Cold Spring Harb Perspect Biol. 2013 Jan 01;5(1):a007898
pubmed: 23169527
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cancer Cell Int. 2014 May 16;14:41
pubmed: 24883045
Am J Cancer Res. 2018 Feb 01;8(2):302-316
pubmed: 29511600
Mol Cancer Res. 2012 Nov;10(11):1403-18
pubmed: 23024188
PLoS One. 2013 Apr 30;8(4):e61901
pubmed: 23637926
Oncol Lett. 2017 Jun;13(6):4657-4660
pubmed: 28599466
J Urol. 2010 Aug;184(2):423-31
pubmed: 20620393
Oncotarget. 2017 Jun 28;8(44):76116-76128
pubmed: 29100297
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Clin Cancer Res. 2018 Oct 1;24(19):4820-4833
pubmed: 29921731